<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279720</url>
  </required_header>
  <id_info>
    <org_study_id>03MI14</org_study_id>
    <nct_id>NCT01279720</nct_id>
  </id_info>
  <brief_title>Gene Therapy ADA Deficiency</brief_title>
  <official_title>Phase I Gene Therapy Protocol for Adenosine Deaminase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Great Ormond Street Hospital for Children NHS Foundation Trust</source>
  <brief_summary>
    <textblock>
      Adenosine deaminase deficiency is an inherited disorder that results in severe abnormalities
      of the immune system and leaves children unable to fight infection. This trial aims to treat
      adenosine deaminase deficiency patients using gene therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological reconstitution</measure>
    <time_frame>5 years</time_frame>
    <description>Measurement of Immunological reconstitution and Metabolic Correction. 5 year follow up of the last patient enrolled into study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of adverse reactions. 5 year follow up of the last patient enrolled into study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular characterisation of gene transfer</measure>
    <time_frame>5 years</time_frame>
    <description>Molecular characterisation of gene transfer. 5 year follow up of the last patient enrolled into study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalisation of nutritional status, growth, and development</measure>
    <time_frame>5 years</time_frame>
    <description>Normalisation of nutritional status, growth, and development. 5 year follow up of the last patient enrolled into study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Adenosine Deaminase Deficiency</condition>
  <arm_group>
    <arm_group_label>Intravenous infusion of transduced cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of transduced cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous infusion of transduced cells</intervention_name>
    <description>Intravenous infusion of transduced cells</description>
    <arm_group_label>Intravenous infusion of transduced cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who lack a human leukocyte antigen (HLA)-genotypically identical bone marrow
             donor OR phenotypically matched family or unrelated donor AND who show incomplete
             immune reconstitution on Polyethylene glycol-modified adenosine deaminase (PEG-ADA)
             enzyme replacement therapy (defined by absolute CD4+ count &lt;300 cell/mm3 and who
             remain on immunoglobulin replacement therapy)

          2. Diagnosis of ADA-SCID (Severe combined immunodeficiency (SCID) due to adenosine
             deaminase (ADA)confirmed by DNA sequencing OR by confirmed absence of &lt;3% of ADA
             enzymatic activity in peripheral blood or (for neonates) in umbilical cord blood
             erythrocytes and/or leukocytes or in cultured fetal cells derived from either
             chorionic villus biopsy or amniocentesis, prior to institution of PEG-ADA replacement
             therapy

          3. Parental/guardian/patient signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002 Jun 28;296(5577):2410-3.</citation>
    <PMID>12089448</PMID>
  </reference>
  <reference>
    <citation>Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996 Feb;3(2):179-83.</citation>
    <PMID>8867866</PMID>
  </reference>
  <reference>
    <citation>Hershfield MS. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat. 1995;5(2):107-12. Review.</citation>
    <PMID>7749407</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenosine deaminase deficiency</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

